||Radioluminescence and Optically Stimulated luminescence studies of AI2O3:C in hadron beams.
Nascimento, Luana ,
Vanhavere, Filip ,
Kodaira, SatoshiKitamura, Hisashi
The capability of radioJuminescence (RL) dosimeters composed of carbon-doped aluminium oxide (Al2O3):C detectors + optical fibre has been verifiedfor absorbed dose-rate measurements during carbon radiotherapy. The RL signals from two separate Al2O3:C detectors (single crystal 'CG' and droplet'Pl1)' have been systematically measured and compared along the Bragg-curve and Spread-Out Bragg-Peak of 290 MeV/n carbon beams in the water.The absorbed dose response was assessed for the range of 0.5 to 10 Gy. For doses up to 6G y，w e observed a linear response for both types of detectors，while for higher doses CG presented a more prominent supraliearity than Pl. The RL response for low-LET protons in the plateau region of the Braggcurve was found to closely resemble that observed for a clinical 6MV X-ray beam，while it was found that P1 has a better agreement with the reference data from standard ionization chamber than CG. We observed a significant decrease in luminescence efficiency with LET in the Bragg peak region. Thesludy implies that the RL-signal from AI2O3:C could potentially be suitable tor medical carbon dosimetry in the plateau range even without any LET-dependentcorrcction factors. which will be a promising tool for in-vivo therapeutic carbon beam dosimetry. A portable and robust instrument has been developedfor the routine assessment of patient exposure to ionizing radiation during radiotherapy treatments. The design principles of hardware and software weredescribed，along with mesurementsthat illustrate the operation of the system and its capabilities， and presented during the 17th Solid State Dosimetry in2013 . This prototype uses radioluminescence (RL) and Optically Stimulated Luminescence (OSL) from AI2O3:C detectors coupled to a PMMA opticalfiber to acquire dose in medical dosimetry. In principle，the RL/OSL prototype can provide two independent dose estimates from the same in vivotreatment: one integrated dose estimate (OSL) and one real-time dose estimate (RL)， which can be compared to one another. This report presents thepreliminary results and future work.